Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

DelveInsight’s 'Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline non-cystic fibrosis bronchiectasis therapies in various stages of ...

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

This review discussed experimental mouse models used in the pre-clinical study of liver fibrosis regression, a pivotal ...

11月7日至10日，由亚太呼吸学会和香港胸肺学会联合主办的2024年第28届亚太呼吸学会年会（APSR ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Although antifibrotic agents can contribute to suppressing renal function decline when administered in combination with ...

Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH –– ...

High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both ...